Alfredo Falcone

Research interests

Publications

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.02.005

• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00727-4

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Quantitative evidence for early metastatic seeding in colorectal cancer

  Nature Genetics · 2019 · https://doi.org/10.1038/s41588-019-0423-x

• Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30791-5

• Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30027-0

• Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31257-1

• Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.5080

• ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

  JNCI Journal of the National Cancer Institute · 2017 · https://doi.org/10.1093/jnci/djx089

• The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients

  European Urology · 2016 · 10.1016/j.eururo.2016.08.012

• Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30500-9

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00122-9

• Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00138-2

• A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

  Journal of Gastrointestinal Cancer · 2015 · https://doi.org/10.1007/s12029-015-9724-1

• Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414325

• Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

  JNCI Journal of the National Cancer Institute · 2015 · 10.1093/jnci/dju427

• Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

  Nature Medicine · 2015 · https://doi.org/10.1038/nm.3870

• Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1403108

• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61900-x

• MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

  Cancer Research · 2010 · https://doi.org/10.1158/0008-5472.can-09-4467

• PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.2796

• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  British Journal of Cancer · 2009 · https://doi.org/10.1038/sj.bjc.6605177

• Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.09.0928

Current projects

No projects listed.